Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jinxin Fertility Group Ltd. ( (HK:1951) ) just unveiled an announcement.
Jinxin Fertility Group has proposed a final dividend of about RMB100 million for 2025, equal to roughly 20% of its non-IFRS adjusted EBITDA, despite industry headwinds and internal management transition. The payout, subject to shareholder approval, signals management’s intention to maintain cash returns and recognize investor support during a challenging period.
The company also launched a three-year shareholder return plan for 2026–2028 targeting total returns of 50%–80% of non-IFRS adjusted EBITDA through a mix of dividends and share buy-backs. As part of this strategy, the board approved up to RMB300 million in open-market repurchases over the next 12 months and revised its dividend policy so that at least 20% of annual non-IFRS adjusted EBITDA will be allocated to cash dividends, strengthening visibility and predictability of shareholder returns.
The most recent analyst rating on (HK:1951) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.
More about Jinxin Fertility Group Ltd.
Jinxin Fertility Group Limited is a Cayman Islands–incorporated company listed in Hong Kong that operates in the assisted reproductive and fertility services sector. The group runs fertility hospitals and clinics, with a focus on in vitro fertilization and related medical services, serving patients in mainland China and other markets in the region.
Average Trading Volume: 21,098,600
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.07B
Find detailed analytics on 1951 stock on TipRanks’ Stock Analysis page.